Categories News Press Releases Archives 2024 September August July June May April March February January 2023 December November October September August July June May April March February January 2022 December November October September August July June May April March February January 2021 December November October September August July June May April March February January 2020 December November October September August July June May April March February January 2019 December November October September August July June May April March February January 2018 December November October September August July June May April March February January Sep 30 UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis Read More Share:| | Jun 12 UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 Read More Share:| | May 06 Evolving Expectations for Arthritis Management Read More Share:| | Nov 09 Advancing Rheumatic Disease Treatment Read More Share:| | Dec 07 The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis Read More Share:| | Nov 17 Shaping the Future of Psoriatic Arthritis Care in Rural Settings Read More Share:| | Nov 10 Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis Read More Share:| | Nov 09 Moving the Conversation Forward in Rheumatology – UCB at ACR Convergence 2022 Read More Share:| | Nov 08 UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022 Read More Share:| | Sep 01 UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress Read More Share:| | Pagination Current page 1 Page 2 Next page Next › Last page